Inhibikase Therapeutics, Inc. (IKT) Balance Sheet
IKT balance sheet, 2025
December 31, 2025 · U.S. dollars$181.2M assets = $8.3M liabilities + $172.9M equity
Both columns are drawn to the same scale: what IKT owns equals what it owes plus shareholders’ equity. Hover a block for its value.
IKT financial health
Equity / assets95.4%
Equity-funded · of assets funded by shareholders
Goodwill & intangibles0.0%
Mostly tangible · of total assets
Descriptive bands, not a rating. Fiscal 2025.
IKT balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $162,9272016 | $181.2M2025 | +118.0%/yr | |
| Total liabilities | $1.5M2016 | $8.3M2025 | +20.8%/yr | |
| Shareholders’ equity | −$1.4M2016 | $172.9M2025 | — | |
| Cash & short-term investments | $12,0362016 | $178.8M2025 | +190.8%/yr | |
| Total debt | $328,9422016 | $110,5172024 | −12.7%/yr | |
| Net cash (debt) | −$316,9062016 | $97.4M2024 | +$97.7M | |
| Working capital | −$1.4M2016 | $171.8M2025 | +$173.2M | |
| Debt / equity | 0.032020 | 0.002024 | −0.03 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
IKT assets
Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current
IKT liabilities and equity
Current liabilitiesLong-term debtOther long-term liabilitiesEquity
IKT debt vs cash
Total debtCash & ST investmentsNet cash (debt)
Debt includes short- and long-term borrowings and, where reported, lease obligations.
IKT balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $178.8M | $97.5M | $13.3M | $23.1M | $40.8M | $14.0M | $18,457 | $379,557 | $16,665 | $12,036 |
| Cash & equivalents | $139.2M | $56.5M | $9.2M | $7.2M | $40.8M | $14.0M | $18,457 | $379,557 | $16,665 | $12,036 |
| Short-term investments | $39.5M | $41.1M | $4.1M | $15.9M | $0 | — | — | — | — | — |
| Receivables | $0 | $0 | $39,881 | $39,881 | $110,141 | $0 | $0 | $472,941 | $180,780 | $66,878 |
| Inventory | $0 | $0 | $1.1M | $1.1M | $107,000 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.3M | $907,782 | $0 | $163,452 | $1.5M | $829,193 | $16,924 | $399,086 | $625 | $1,250 |
| Total current assets | $180.1M | $98.5M | $14.2M | $24.4M | $42.5M | $14.8M | $35,381 | $1.3M | $198,070 | $80,164 |
| Property, plant & equipment (net) | $0 | $148,537 | $295,599 | $565,175 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.1M | $0 | $0 | $0 | $0 | $0 | $2,873 | $1.6M | $87,097 | $82,763 |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M | $14.8M | $38,254 | $2.8M | $285,167 | $162,927 |
| Liabilities | ||||||||||
| Accounts payable | $1.2M | $943,019 | $646,767 | $1.2M | $1.1M | $1.7M | $1.0M | $954,238 | $353,521 | $431,791 |
| Short-term debt | — | $110,517 | $531,879 | $145,836 | $248,911 | $42,534 | $98,419 | $233,729 | $459,962 | $328,942 |
| Deferred revenue | — | — | — | — | — | $2.3M | $1.4M | $262,368 | $5,641 | — |
| Total current liabilities | $8.3M | $3.7M | $3.4M | $3.7M | $4.1M | $4.7M | $4.3M | $3.6M | $1.7M | $1.5M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $276,461 | $275,375 | $0 | $0 | $0 |
| Lease obligations | $0 | $110,517 | $240,219 | $351,287 | $0 | — | — | — | — | — |
| Other long-term liabilities | $0 | $0 | $90,124 | $205,451 | $0 | $0 | $0 | $1.5M | $0 | $0 |
| Total liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M | $5.0M | $4.5M | $3.6M | $1.7M | $1.5M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $131,691 | $69,362 | $6,186 | $4,224 | $25,155 | $10,051 | $8,181 | $8,181 | $8,920 | $8,920 |
| Retained earnings (deficit) | −$142.7M | −$94.4M | −$66.9M | −$47.9M | −$29.8M | −$15.0M | −$12.2M | −$6.5M | −$4.3M | −$3.9M |
| Accumulated other comprehensive income | $21,802 | −$37,248 | $877 | $104,718 | $0 | $0 | — | — | — | — |
| Total shareholders' equity | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M | $9.8M | −$4.5M | −$777,965 | −$1.4M | −$1.4M |
| Key figures | ||||||||||
| Total debt | — | $110,517 | $622,003 | $351,287 | $248,911 | $318,995 | $373,794 | $233,729 | $459,962 | $328,942 |
| Net cash (debt) | — | $97.4M | $12.6M | $22.7M | $40.5M | $13.6M | −$355,337 | $145,828 | −$443,297 | −$316,906 |
| Working capital | $171.8M | $94.7M | $10.8M | $20.7M | $38.4M | $10.1M | −$4.2M | −$2.4M | −$1.5M | −$1.4M |
| Tangible book value | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M | $9.8M | −$4.5M | −$777,965 | −$1.4M | −$1.4M |
| Book value per share | $1.76 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 98.3M | — | — | — | — | — | — | — | — | — |
| Current ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | 3.13 | 0.01 | 0.35 | 0.11 | 0.05 |
| Quick ratio | 21.54 | 26.13 | 3.87 | 6.25 | 10.08 | 2.96 | 0.00 | 0.24 | 0.11 | 0.05 |
| Debt / equity | — | 0.00 | 0.06 | 0.02 | 0.01 | 0.03 | — | — | — | — |
| Equity / assets | 95.4% | 96.2% | 75.7% | 84.4% | 90.5% | 66.2% | −11,737.4% | −27.3% | −505.3% | −829.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $159.0M | $170.4M | $178.8M | $77.3M | $87.7M | $93.2M | $97.5M | $3.2M | $7.9M | $9.7M | $13.3M | $16.8M |
| Cash & equivalents | $31.2M | $49.6M | $139.2M | $38.3M | $77.7M | $73.4M | $56.5M | $913,420 | $3.1M | $2.4M | $9.2M | $14.9M |
| Short-term investments | $127.8M | $120.8M | $39.5M | $39.1M | $9.9M | $19.7M | $41.1M | $2.3M | $4.9M | $7.4M | $4.1M | $2.0M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $39,881 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.1M |
| Other current assets | $3.3M | $1.8M | $1.3M | $1.2M | $1.1M | $984,467 | $907,782 | $946,457 | $662,787 | $1.1M | $958,996 | $0 |
| Total current assets | $162.3M | $172.2M | $180.1M | $78.5M | $88.8M | $94.2M | $98.5M | $4.2M | $8.6M | $10.8M | $14.2M | $17.6M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $58,605 | $116,564 | $148,537 | $186,772 | $223,997 | $260,264 | $295,599 | $330,030 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.2M | $1.2M | $1.1M | $1.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $163.6M | $173.3M | $181.2M | $79.6M | $88.9M | $94.3M | $98.6M | $4.4M | $8.8M | $11.1M | $14.5M | $17.9M |
| Liabilities | ||||||||||||
| Accounts payable | $991,720 | $1.6M | $1.2M | $620,528 | $2.7M | $1.7M | $943,019 | $2.5M | $1.3M | $1.3M | $646,767 | $734,561 |
| Short-term debt | — | — | — | — | $37,944 | $74,772 | $110,517 | $216,872 | $329,480 | $431,773 | $531,879 | $149,030 |
| Total current liabilities | $10.3M | $5.7M | $8.3M | $6.7M | $8.8M | $8.6M | $3.7M | $4.9M | $3.7M | $4.2M | $3.4M | $2.7M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | $0 | $0 | $37,944 | $74,772 | $110,517 | $145,210 | $177,830 | $209,489 | $240,219 | $270,043 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $25,606 | $58,330 | $90,124 | $121,013 |
| Total liabilities | $10.3M | $5.7M | $8.3M | $6.7M | $8.8M | $8.6M | $3.7M | $4.9M | $3.7M | $4.3M | $3.5M | $2.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $132,032 | $132,032 | $131,691 | $74,808 | $74,516 | $74,341 | $69,362 | $7,464 | $7,216 | $6,477 | $6,186 | $5,361 |
| Retained earnings (deficit) | −$178.7M | −$159.1M | −$142.7M | −$129.9M | −$118.0M | −$108.1M | −$94.4M | −$82.3M | −$76.5M | −$71.6M | −$66.9M | −$62.7M |
| Accumulated other comprehensive income | −$72,754 | −$26,293 | $21,802 | −$4,189 | −$2,944 | −$967 | −$37,248 | $1,754 | −$1,024 | −$1,800 | $877 | −$143 |
| Total shareholders' equity | $153.3M | $167.6M | $172.9M | $72.9M | $80.1M | $85.7M | $94.9M | −$530,591 | $5.1M | $6.8M | $11.0M | $15.0M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | $37,944 | $74,772 | $110,517 | $216,872 | $355,086 | $490,103 | $622,003 | $270,043 |
| Net cash (debt) | — | — | — | — | $87.6M | $93.1M | $97.4M | $3.0M | $7.6M | $9.3M | $12.6M | $16.6M |
| Working capital | $152.1M | $166.5M | $171.8M | $71.8M | $80.0M | $85.6M | $94.7M | −$717,363 | $4.9M | $6.6M | $10.8M | $14.8M |
| Tangible book value | $153.3M | $167.6M | $172.9M | $72.9M | $80.1M | $85.7M | $94.9M | −$530,591 | $5.1M | $6.8M | $11.0M | $15.0M |
| Book value per share | $0.88 | $0.97 | $1.84 | $0.81 | $0.89 | $0.96 | — | — | — | — | — | — |
| Shares outstanding | 174.6M | 172.3M | 94.2M | 90.1M | 90.0M | 89.5M | — | — | — | — | — | — |
| Current ratio | 15.82 | 30.14 | 21.70 | 11.73 | 10.09 | 11.01 | 26.37 | 0.85 | 2.32 | 2.55 | 4.13 | 6.40 |
| Quick ratio | 15.50 | 29.83 | 21.54 | 11.55 | 9.96 | 10.90 | 26.13 | 0.66 | 2.14 | 2.30 | 3.85 | 6.15 |
| Debt / equity | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.07 | 0.07 | 0.06 | 0.02 |
| Equity / assets | 93.7% | 96.7% | 95.4% | 91.6% | 90.1% | 90.9% | 96.2% | −12.1% | 57.7% | 61.2% | 75.7% | 84.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 26, 2026); data from EODHD.
IKT financial position
At the end of fiscal 2025 (December 31, 2025), Inhibikase Therapeutics had total assets of $181.2 million (up 83.8% from a year earlier), total liabilities of $8.3 million and shareholders' equity of $172.9 million. Its current ratio was 21.70. In the latest quarter (ended June 30, 2026) total assets were $163.6 million and equity $153.3 million.
Related: IKT income statement, IKT cash flow statement, IKT key metrics. See the IKT stock overview for the latest quote and news.
IKT balance sheet FAQ
What are Inhibikase Therapeutics's total assets?
Inhibikase Therapeutics reported total assets of $181.2 million at the end of fiscal 2025 (December 31, 2025), compared with $98.6 million a year earlier.
How much cash does Inhibikase Therapeutics have?
Inhibikase Therapeutics held $178.8 million in cash and short-term investments at the end of fiscal 2025.
What is Inhibikase Therapeutics's book value?
Inhibikase Therapeutics's shareholders' equity (book value) was $172.9 million at the end of fiscal 2025, or $1.76 per share.
What is Inhibikase Therapeutics's current ratio?
Inhibikase Therapeutics had current assets of $180.1 million and current liabilities of $8.3 million, a current ratio of 21.70 (it can cover its short-term obligations).